Iterum Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Iterum Therapeutics PLC
ITRM Stock  USD 0.34  0.01  2.60%   
Iterum Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Iterum Therapeutics' valuation are provided below:
Gross Profit
116 K
Market Capitalization
18.9 M
Enterprise Value Revenue
100.8583
Revenue
390 K
Earnings Share
(0.72)
There are over one hundred nineteen available fundamental trends for Iterum Therapeutics PLC, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to confirm Iterum Therapeutics' regular fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road.

Iterum Therapeutics Total Revenue

37,000

Check Iterum Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iterum Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 493 K, Interest Income of 1 M or Depreciation And Amortization of 242.8 K, as well as many indicators such as Price To Sales Ratio of 1.8 K, Dividend Yield of 0.0 or Days Sales Outstanding of 10.3 K. Iterum financial statements analysis is a perfect complement when working with Iterum Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Iterum Stock
Check out the analysis of Iterum Therapeutics Correlation against competitors.

Iterum Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets56.1 M51.3 M42.8 M
Slightly volatile
Other Current Liabilities3.2 M3.3 M5.9 M
Pretty Stable
Total Current Liabilities19 M20.2 M12.9 M
Slightly volatile
Accounts Payable214.6 K225.9 K2.5 M
Very volatile
Cash15.6 M21.7 M21.3 M
Slightly volatile
Non Current Assets Total23.9 M22.8 M8 M
Slightly volatile
Non Currrent Assets Other33.3 K35.1 K2.8 M
Very volatile
Other Assets907.9 K955.6 K2.3 M
Pretty Stable
Cash And Short Term Investments31.8 M21.7 M33 M
Pretty Stable
Net Receivables56.4 K59.4 K414.9 K
Very volatile
Common Stock Total Equity596.5 K568.1 K232.9 K
Slightly volatile
Common Stock Shares Outstanding13.4 M22.7 M13.5 M
Pretty Stable
Liabilities And Stockholders Equity56.1 M51.3 M42.8 M
Slightly volatile
Non Current Liabilities Total27.9 M35.7 M17.2 M
Slightly volatile
Capital Surpluse173.8 M271.3 M145.1 M
Slightly volatile
Other Current Assets509.6 K536.4 K1.9 M
Pretty Stable
Other Stockholder Equity318.3 M553.9 M221.5 M
Slightly volatile
Total Liabilities40.9 M56 M26.9 M
Slightly volatile
Preferred Stock Total Equity47.9 K65.5 K45.8 K
Slightly volatile
Total Current Assets33.5 M22.3 M34.6 M
Pretty Stable
Common Stock390.9 K362.2 K233.8 K
Slightly volatile
Other Liabilities4.1 M4 M1.5 M
Slightly volatile
Property Plant And Equipment Net19.7 K20.7 K1.1 M
Very volatile
Property Plant And Equipment Gross310.4 K326.7 K994.7 K
Very volatile
Non Current Liabilities Other205.4 K216.2 K2.4 M
Pretty Stable
Property Plant Equipment1.5 M1.7 M1.4 M
Pretty Stable
Short and Long Term Debt Total31.5 M52.4 M23.4 M
Slightly volatile
Long Term Debt23 M35.7 M18.2 M
Slightly volatile
Long Term Debt Total15.8 M25.8 M16.4 M
Slightly volatile
Short and Long Term Debt17.5 M16.6 M5.9 M
Slightly volatile
Capital Stock501.3 K362.2 K306.2 K
Slightly volatile
Short Term Debt17.5 M16.6 M4.3 M
Slightly volatile
Intangible Assets23.8 M22.7 M7.6 M
Slightly volatile

Iterum Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision493 K276 K322.4 K
Slightly volatile
Depreciation And Amortization242.8 K255.6 K5.9 M
Slightly volatile
Selling General Administrative9.9 M9.2 M7 M
Slightly volatile
Other Operating Expenses33.4 M16.8 M29.8 M
Slightly volatile
Research Development8.9 M9.4 M21.6 M
Pretty Stable
Total Operating Expenses32.9 M16.6 M29.4 M
Slightly volatile
Income Tax Expense498.1 K276 K325.1 K
Slightly volatile
Reconciled Depreciation310.3 K326.6 K443.7 K
Slightly volatile
Non Operating Income Net Other156.8 K176.4 K192.5 K
Slightly volatile
Selling And Marketing Expenses6 M6.7 M7.3 M
Slightly volatile

Iterum Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock31.7 M22.4 M28.1 M
Very volatile
Stock Based Compensation396.6 K417.4 K2.2 M
Pretty Stable
Begin Period Cash Flow5.2 M5.5 M15.9 M
Pretty Stable
Capital Expenditures1.7 K1.8 K397.8 K
Slightly volatile
End Period Cash Flow15.7 M21.7 M21.3 M
Slightly volatile
Change To Netincome16.8 M22.4 M11 M
Slightly volatile
Issuance Of Capital Stock39 M24 M73.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.8 K1.7 K985
Slightly volatile
Days Sales Outstanding10.3 K9.8 K5.2 K
Slightly volatile
Stock Based Compensation To Revenue55.552.8627.5527
Slightly volatile
Capex To Depreciation0.00770.00815.9365
Slightly volatile
EV To Sales1.9 K1.8 K1 K
Slightly volatile
Payables Turnover0.540.910.6616
Pretty Stable
Sales General And Administrative To Revenue288274145
Slightly volatile
Research And Ddevelopement To Revenue2.3 K2.2 K1.2 K
Slightly volatile
Capex To Revenue0.860.751.0819
Slightly volatile
Cash Per Share1.341.4114.1861
Very volatile
Days Payables Outstanding721415579
Pretty Stable
Income Quality0.91.240.8557
Pretty Stable
Intangibles To Total Assets0.420.40.1283
Slightly volatile
Current Ratio1.541.624.4981
Slightly volatile
Receivables Turnover0.03660.03850.5568
Slightly volatile
Capex Per Share1.0E-41.0E-40.7063
Slightly volatile
Revenue Per Share0.03850.04050.5333
Slightly volatile
Interest Debt Per Share2.532.6612.8283
Slightly volatile
Debt To Assets0.50.920.4065
Slightly volatile
Operating Cycle10.3 K9.8 K5.2 K
Slightly volatile
Days Of Payables Outstanding721415579
Pretty Stable
Ebt Per Ebit1.141.181.245
Slightly volatile
Quick Ratio1.541.624.5487
Slightly volatile
Net Income Per E B T0.810.910.9918
Slightly volatile
Cash Ratio2.131.583.3209
Slightly volatile
Days Of Sales Outstanding10.3 K9.8 K5.2 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0277
Slightly volatile
Fixed Asset Turnover0.07070.07440.4244
Slightly volatile
Debt Ratio0.50.920.4065
Slightly volatile
Price Sales Ratio1.8 K1.7 K985
Slightly volatile
Asset Turnover0.00160.00170.0063
Slightly volatile

Iterum Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap84.3 M54.6 M77.5 M
Slightly volatile
Enterprise Value17.5 M18.4 M54.5 M
Slightly volatile

Iterum Fundamental Market Drivers

Iterum Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Iterum Therapeutics Financial Statements

Iterum Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Iterum Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-298.8 K-283.9 K
Cost Of Revenue228.6 K217.2 K
Stock Based Compensation To Revenue 52.86  55.50 
Sales General And Administrative To Revenue 274.48  288.20 
Research And Ddevelopement To Revenue2.2 K2.3 K
Capex To Revenue 0.75  0.86 
Revenue Per Share 0.04  0.04 
Ebit Per Revenue-3.2 K-3 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Iterum Therapeutics PLC is a strong investment it is important to analyze Iterum Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iterum Therapeutics' future performance. For an informed investment choice regarding Iterum Stock, refer to the following important reports:
How To Invest In Iterum
Details
Is Iterum Stock a good investment?
Details
What is Iterum Therapeutics' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Iterum Therapeutics Correlation against competitors.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.72)
Revenue Per Share
0.011
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.53)
Return On Equity
(5.56)
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY